Insider · SEC Form 4 filer
Ali Behbahani
Companies
Where they file as an insider
Black Diamond Therapeutics (BDTX) Director Latest filing Sep 18, 2026
Crispr Therapeutics AG (CRSP) Director Latest filing Sep 17, 2026
Monte Rosa Therapeutics (GLUE) Director Latest filing Jul 1, 2026
Arcellx (ACLX) Director Latest filing Apr 28, 2026
Korro Bio (KRRO) Director, 10% owner Latest filing Mar 10, 2026
SpyGlass Pharma (SGP) Director, 10% owner Latest filing Feb 9, 2026
NeueHealth (NEUE) Director, 10% owner Latest filing Oct 2, 2025
Adaptimmune Therapeutics (ADAP) Director Latest filing Aug 18, 2025
And 2 more companies with older filings.
Track record
Did their buys beat the typical stock?
Open-market buys1
Quarters checked 6 months later1
Beat the typical stock —
Quarters too new to check0
Too soon to tell. 1 quarter has finished so far. We show a record once 3 have.
SpyGlass Pharma (SGP) Bought Feb 9, 2026 · $15M · 937,500 shares Behind typical Mar 31, 2026 $25.91 → Sep 30, 2026 $26.00 · +0.3% (typical stock +1.7%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.